Purchase Agreement, dated January 16, 2013



 Exhibit 10.1 
 EXECUTION VERSION 
 $300,000,000 

BROCADE COMMUNICATIONS SYSTEMS, INC. 
 4.625% Senior Notes due 2023 
 PURCHASE AGREEMENT 

January 16, 2013 








                    January 16,
2013 
 Morgan Stanley & Co. LLC 
 J.P. Morgan Securities LLC 
 As Representatives of the Initial Purchasers 

c/o Morgan Stanley & Co. LLC 

      1585 Broadway 

      New York, New York 10036 
 c/o J.P. Morgan Securities LLC 
       383 Madison Avenue 

      New York, New York 10179 
 Ladies and Gentlemen: 
 Brocade Communications Systems, Inc., a Delaware
corporation (the “Company”), proposes to issue and sell to the several purchasers named in Schedule I hereto (the “Initial Purchasers”) $300,000,000 aggregate principal amount of the Company’s 4.625%
Senior Notes due 2023 (the “Notes”). Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC have agreed to act as the representatives of the several Initial Purchasers (the “Representatives”) in connection
with the offering and sale of the Notes. 
 The Securities (as defined herein) will be issued pursuant to the provisions of an
indenture, to be dated as of January 22, 2013 (the “Indenture”), among the Company, the Guarantors (as defined herein) and Wells Fargo Bank, National Association as trustee (the “Trustee”). 

Holders of Notes will be entitled to the benefits of a registration rights agreement, to be dated as of January 22, 2013 (the
“Registration Rights Agreement”), among the Company, the Guarantors and the Initial Purchasers, pursuant to which the Company and the Guarantors may be required to file with the Commission (as defined herein), under the
circumstances set forth therein, (i) a registration statement under the Securities Act (as defined herein) relating to another series of debt securities of the Company with terms substantially identical to the Notes (the “Exchange
Notes”) to be offered in exchange for the Notes (the “Exchange Offer”) and (ii) a shelf registration statement pursuant to Rule 415 of the Securities Act relating to the resale by certain holders of the Notes and, in
each case, to use its commercially reasonable efforts to cause such registration statement to be declared effective. All references herein to the Exchange Notes and the Exchange Offer are only applicable if the Company and the Guarantors are in fact
required to consummate the Exchange Offer pursuant to the terms of the Registration Rights Agreement. 







 The payment of principal of, premium, if any, and interest on the Notes will be fully and
unconditionally guaranteed on a senior unsecured basis, jointly and severally, by (i) the entities listed on the signature pages hereof as “Guarantors” and (ii) any subsidiary of the Company formed or acquired after the
Closing Date that executes an additional guarantee in accordance with the terms of the Indenture, and their respective successors and assigns (collectively, the “Guarantors”), pursuant to their guarantees (the
“Guarantees”). The Notes and the Guarantees attached thereto are herein collectively referred to as the “Securities”; and the Exchange Notes and the Guarantees attached thereto are herein collectively referred to as
the “Exchange Securities.” 
 The Company understands that the Initial Purchasers propose to make an offering
of the Securities on the terms and in the manner set forth herein and in the Time of Sale Memorandum (as defined herein) and agrees that the Initial Purchasers may resell, subject to the conditions set forth herein, all or a portion of the
Securities to purchasers (the “Subsequent Purchasers”) on the terms set forth in the Time of Sale Memorandum (the first time when sales of the Securities are made is referred to as the “Time of Sale”). The
Securities will be offered without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to persons the Initial Purchasers reasonably believe to be qualified institutional buyers in compliance with
the exemption from registration provided by Rule 144A under the Securities Act (“Rule 144A”) and in offshore transactions in reliance on Regulation S under the Securities Act (“Regulation S”). Pursuant to the terms
of the Securities and the Indenture, investors who acquire Securities shall be deemed to have agreed that Securities may only be resold or otherwise transferred, after the date hereof, if such Securities are registered for sale under the Securities
Act or if an exemption from the registration requirements of the Securities Act is available (including the exemptions afforded by Rule 144A or Regulation S). The Company hereby confirms that it has authorized the use of the Time of Sale Memorandum
and the Final Memorandum (as defined herein) in connection with the offer and sale of the Securities by the Initial Purchasers. 

In connection with the sale of the Securities, the Company has prepared and delivered to each Initial Purchaser copies of a preliminary
offering memorandum, dated January 16, 2013 (the “Preliminary Memorandum”), and prepared and delivered to each Initial Purchaser copies of a pricing supplement, dated January 16, 2013 (the “Pricing
Supplement”), describing the terms of the Securities, each for use by such Initial Purchaser in connection with its solicitation of offers to purchase the Securities. The Preliminary Memorandum and the Pricing Supplement are herein referred
to as the “Time of Sale Memorandum.” Promptly after this Agreement is executed and delivered, the Company will prepare and deliver to each Initial Purchaser a final offering memorandum, dated the date hereof (the “Final
Memorandum”). As used herein, the terms “Preliminary Memorandum,” “Time of Sale Memorandum” and “Final Memorandum” shall include the documents, if any, incorporated by reference therein on the date hereof. The
terms “supplement”, “amendment” and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum shall include all documents subsequently
filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are deemed to be


  
 2 








 
incorporated by reference therein. For purposes of this Agreement, “Additional Written Offering Communication” means any written communication (as defined in Rule 405 under the
Securities Act) that constitutes an offer to sell or a solicitation of an offer to buy the Securities other than the Preliminary Memorandum and the Final Memorandum. 
 1. Representations and Warranties. Each of the Company and the Guarantors, jointly and severally, hereby represents and warrants to, and agrees with each Initial Purchaser that, as of the Time of
Sale and as of the Closing Date (as defined in Section 4): 
 (a) (i) Each document, if any, filed or to be
filed pursuant to the Exchange Act and incorporated by reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum complied or will comply when so filed in all material respects with the Exchange Act and the
applicable rules and regulations of the Commission thereunder, (ii) the Time of Sale Memorandum as of the Time of Sale does not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iii) the Final Memorandum as of its date and as of the Closing Date will not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not
apply to statements in or omissions from the Time of Sale Memorandum or the Final Memorandum based upon information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use
therein. 
 (b) Except for the Additional Written Offering Communications, if any, identified in Schedule II
hereto and furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any Additional Written Offering Communication. 

(c) The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Memorandum, and to enter into and perform its obligations under each of this Agreement, the
Indenture, the Registration Rights Agreement, the Securities and the Exchange Securities. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or
leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would have a material adverse effect on the Company and its subsidiaries, taken as a whole. 

  
 3 








 (d) Each Guarantor and Significant Subsidiary (as defined below) has been
duly incorporated or formed, as applicable, is validly existing as a corporation, limited liability company or partnership, as applicable, in good standing under the laws of the jurisdiction of its incorporation or formation, as applicable, has the
corporate, company or partnership power, as applicable, and authority to own its property and to conduct its business as described in the Time of Sale Memorandum and to enter into and perform its obligations under each of this Agreement, the
Indenture, the Registration Rights Agreement, the Securities and the Exchange Securities, as applicable. Each Guarantor and Significant Subsidiary is duly qualified to transact business and is in good standing in each jurisdiction in which the
conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the
Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign
subsidiary, for directors’ qualifying shares and except as otherwise disclosed in each of the Time of Sale Memorandum and the Final Memorandum) and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances,
equities or claims, except those existing under the Credit Agreement (as defined herein), the Company’s 6.625% Senior Secured Notes due 2018 or the Company’s 6.875% Senior Secured Notes due 2020 or that will constitute Permitted Liens (as
will be defined in the Indenture, “Permitted Liens”). The subsidiaries listed in Schedule III to this Agreement are the only significant subsidiaries (as defined in Rule 1-02 of Regulation S-X under the Exchange Act) of the Company
(the “Significant Subsidiaries”) and no other subsidiary or subsidiaries of the Company, individually or in the aggregate, constitutes or constitute a significant subsidiary (as defined in Rule 1-02 of Regulation S-X under the
Exchange Act) of the Company. 
 (e) This Agreement has been duly authorized, executed and delivered by the
Company and each Guarantor. 
 (f) The Notes have been duly authorized and, when executed and authenticated in
accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid and binding obligations of the Company, enforceable in accordance with their terms,
subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability, and will be entitled to the benefits of the Indenture pursuant to which such Notes are to be
issued. 
 (g) The Exchange Notes have been duly authorized and, if and when executed and authenticated in
accordance with the provisions of the Indenture, the Registration Rights Agreement and the Exchange Offer, will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to applicable
bankruptcy, insolvency and similar laws 

  
 4 








 
affecting creditors’ rights generally and equitable principles of general applicability, and will be entitled to the benefits of the Indenture pursuant to which such Exchange Notes are to be
issued. 
 (h) The Guarantees of the Notes on the Closing Date and the Guarantees of the Exchange Notes if and
when issued will be in the respective forms contemplated by the Indenture and have been duly authorized for issuance pursuant to this Agreement and the Indenture; the Guarantees of the Notes, when the Notes have been authenticated in the manner
provided for in the Indenture and issued and delivered against payment of the purchase price therefor, will constitute valid and binding agreements of the Guarantors; and, when the Exchange Notes have been authenticated in the manner provided for in
the Indenture and issued and delivered in accordance with the Registration Rights Agreement, the Guarantees of the Exchange Notes will constitute valid and binding agreements of the Guarantors. The Guarantees of the Notes and of the Exchanges Notes
will, in each case, be enforceable against the Guarantors in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability, and
will be entitled to the benefits of the Indenture pursuant to which such Guarantees are to be issued. 
 (i) Each
of the Indenture and the Registration Rights Agreement has been duly authorized and, on the Closing Date, will have been duly executed and delivered by the Company and each Guarantor, and will constitute a valid and binding agreement of the Company
and each Guarantor, enforceable against the Company and each Guarantor in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general
applicability and except as rights to indemnification and contribution under the Registration Rights Agreement may be limited under applicable law and public policy. On the Closing Date, the Indenture will conform in all material respects to the
requirements of the Trust Indenture Act of 1939, as amended, and the rules and regulations of the Commission applicable to an indenture that is qualified thereunder (the “Trust Indenture Act”). 

(j) The Notes and the Guarantees to be purchased by the Initial Purchasers from the Company will on the Closing Date be in
the form contemplated by the Indenture. The Securities, the Exchange Securities, the Indenture and the Registration Rights Agreement will conform in all material respects to the descriptions thereof in the Time of Sale Memorandum and the Final
Memorandum. 
 (k) At October 27, 2012, on a consolidated basis, after giving pro forma effect to the
issuance and sale of the Notes pursuant hereto and the use of proceeds as described under the caption “Use of Proceeds” in the Time of Sale Memorandum and Final Memorandum, the Company would have an authorized and outstanding
capitalization as set forth in the Time of Sale Memorandum and 

  
 5 








 
the Final Memorandum under the caption “Capitalization” (other than for subsequent issuances of capital stock, if any, pursuant to employee benefit or stock purchase plans described in
the Time of Sale Memorandum and the Final Memorandum or upon exercise of outstanding options or the vesting of restricted stock units described in the Time of Sale Memorandum and the Final Memorandum). 

(l) With respect to the outstanding stock options (the “Stock Options”) granted pursuant to the
stock-based compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum, (i) each Stock Option intended to qualify as
an “incentive stock option” under Section 422 of the Code so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the
“Grant Date”) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the
necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the Company Stock Plans,
the Exchange Act and the rules of the Nasdaq Global Select Market, (iv) the per share exercise price of each Stock Option was equal to the fair market value of a share of Common Stock (as defined in the applicable Company Stock Plan) on the
applicable Grant Date and (v) each such grant was properly accounted for in accordance with U.S. generally accepted accounting principles in the financial statements (including the related notes) of the Company and disclosed in the
Company’s filings with the Commission in accordance with the Exchange Act and all other applicable laws, except in the case of clauses (i)-(v) in such instances that are reasonably expected to not have a material adverse effect on the
Company and its subsidiaries, taken as a whole. Except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum, the Company has not knowingly granted, and there is no and has been no policy or practice of the Company of
granting, Stock Options prior to the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects, except in such instances that are reasonably expected to not
have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (m) Neither the Company
nor any of its subsidiaries is (i) with respect to the Company, any Guarantor or any Significant Subsidiary, in violation of its charter, bylaws or other constitutive document or (ii) in default (or, with the giving of notice or lapse of
time, would be in default) (“Default”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which the Company or any of its subsidiaries is a party or by which it or any of
them may be bound (including, without limitation, the Credit Agreement dated as of October 7, 2008, among the lenders party thereto, Bank of America, N.A., as administrative agent, swing line lender and letter of credit


  
 6 








 
issuer, Morgan Stanley Senior Funding, Inc., as syndication agent, Banc of America Securities LLC and Morgan Stanley Senior Funding, Inc., as joint lead arrangers and joint bookrunners, HSBC Bank
USA National Association and Keybank National Association, as co-documentation agents and the Company, as amended (the “Credit Agreement”); the Company’s 6.625% Senior Secured Notes due 2018; or the Company’s 6.875% Senior
Secured Notes due 2020) or to which any of the property or assets of the Company or any of its subsidiaries is subject (each, an “Existing Instrument”), except, in the case of clause (ii) above, for such Defaults as would not,
individually or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries, taken as a whole. The Company’s execution, delivery and performance of this Agreement, the Registration Rights
Agreement and the Indenture, and the issuance and delivery of the Securities and the Exchange Securities, and consummation of the transactions contemplated hereby and thereby and by the Time of Sale Memorandum and the Final Memorandum (including the
discharge of the Company’s 6.625% Senior Secured Notes due 2018) (i) will not result in any violation of the provisions of the charter, bylaws or other constitutive document of the Company, any Guarantor or any of the Significant
Subsidiaries, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except for such conflicts, breaches, Defaults, liens, charges or encumbrances (x) as have been waived or
otherwise approved pursuant to such Existing Instrument or (y) as would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries, taken as a whole, and
(iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any subsidiary, except for such violations as would not, individually or in the aggregate, reasonably be
expected to result in a material adverse effect on the Company and its subsidiaries, taken as a whole. As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or
lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness
by the Company or any of its subsidiaries. 
 (n) No consent, approval, authorization or other order of, or
registration or filing with, any court or other governmental or regulatory authority or agency is required for the Company’s execution, delivery and performance of this Agreement, the Registration Rights Agreement or the Indenture, or the
issuance and delivery of the Securities or the Exchange Securities, or consummation of the transactions contemplated hereby and thereby and by the Final Memorandum, except for (x) such consents, approvals, authorizations, orders, registrations
or filings, as may be required (i) under applicable state securities laws of the several states of the United States or provinces of Canada in 

  
 7 








 
connection with the purchase and resale of the Securities by the Initial Purchasers and (ii) with respect to the Exchange Securities, under the Securities Act, the Trust Indenture Act and
applicable securities laws of the several states of the United States or provinces of Canada with respect to the Company’s obligations under the Registration Rights Agreement, (y) such consents, approvals, authorizations, orders,
registrations or filings as have been obtained or made by the Company and are in full force and effect and (z) such consents, approvals, authorizations, orders, registrations or filings the failure of which to obtain or make would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the consummation of the offering of the Securities or the transactions contemplated by this
Agreement, the Registration Rights Agreement and the Indenture. 
 (o) Subsequent to the date of the most recent
audited financial statements in each of the Time of Sale Memorandum and the Final Memorandum, there has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or
otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Memorandum provided to prospective purchasers of the Securities. 

(p) Subsequent to the respective dates as of which information is given in each of the Time of Sale Memorandum and the
Final Memorandum, (i) the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction (other than agreements entered into with original equipment
manufacturers in the ordinary course of business consistent with past practice); (ii) the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its
capital stock other than ordinary and customary dividends (other than purchases of common stock pursuant to the Company’s stock repurchase program described in the Time of Sale Memorandum and the Final Memorandum); (iii) there has not been
any material change in the capital stock (other than issuances of capital stock pursuant to employee benefit or stock purchase plans described in the Time of Sale Memorandum and the Final Memorandum or upon exercise of outstanding options or the
vesting of restricted stock units described in the Time of Sale Memorandum and the Final Memorandum, and the grant of options and awards under existing equity incentive plans described in the Time of Sale Memorandum and the Final Memorandum) or long
term debt of the Company and its subsidiaries; and (iv) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as described in each of the Time of Sale Memorandum and the Final Memorandum,
respectively. 

  
 8 








 (q) Other than proceedings accurately described in all material respects in
the Time of Sale Memorandum, there are no legal or governmental proceedings pending or, to the knowledge of the Company or any of the Guarantors, overtly threatened to which the Company or any of its subsidiaries is a party or to which any of the
properties of the Company or any of its subsidiaries is subject that would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its
obligations under this Agreement, the Indenture, the Registration Rights Agreement or the Notes or to consummate the transactions contemplated by the Time of Sale Memorandum. 

(r) Except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum, (i) the Company and its
subsidiaries (x) are in compliance with all applicable federal, state, local and foreign laws, statutes, rules, regulations, requirements, decisions and orders relating to the protection of the environment or natural resources, or to hazardous
or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”), (y) have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of
them under applicable Environmental Laws to conduct their respective businesses, and (z) have not received written notice of any actual or potential liability under or relating to any Environmental Laws, including for the investigation or
remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii) there are no
costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such failure to comply, or failure to receive required permits, licenses,
certificates or other authorizations or approvals, or cost or liability, as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; and
(iii) except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum, (x) there are no proceedings that are pending, or that are known to be contemplated, against the Company or any of its subsidiaries under any
Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not
aware of any issues regarding compliance with, or liabilities or other obligations under, Environmental Laws that could reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, and (z) none
of the Company and its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. 
 (s) There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic wastes or hazardous substances, including, but not
limited to, any naturally occurring radioactive materials, brine, drilling mud, crude oil, natural gas liquids 

  
 9 








 
and other petroleum materials, by, due to or caused by the Company or any of its subsidiaries (or, to the Company’s or any Guarantor’s knowledge, any other entity (including any
predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably be expected to be liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other
property, in violation of any Environmental Laws or in a manner or to a location that could reasonably be expected to give rise to any liability under the Environmental Laws, except for any violation or liability which would not, individually or in
the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (t) The Company and each Guarantor is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Final Memorandum will not be,
required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”). 

(u) None of the Company, any affiliate (as defined in Rule 501(b) of Regulation D under the Securities Act, an
“Affiliate”), or any person acting on its or their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has, directly or indirectly, solicited any offer to buy or offered to sell, or
will, directly or indirectly, solicit any offer to buy or offer to sell, in the United States or to any United States citizen or resident, any security which is or would be integrated with the sale of the Securities in a manner that would require
the Securities to be registered under the Securities Act. None of the Company, its Affiliates, or any person acting on its or any of their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has
engaged or will engage, in connection with the offering of the Securities, in any form of general solicitation or general advertising within the meaning of Rule 502 under the Securities Act. With respect to those Securities sold in reliance upon
Regulation S, (i) none of the Company, its Affiliates or any person acting on its or their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has engaged or will engage in any directed selling
efforts within the meaning of Regulation S and (ii) each of the Company and its Affiliates and any person acting on its or their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has complied
and will comply with the offering restrictions set forth in Regulation S. The Company is a “reporting issuer”, as defined in Rule 902 under the Securities Act. 

(v) Subject to compliance by the Initial Purchasers with the procedures set forth in Section 7 hereof, it is not
necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchasers and to each Subsequent Purchaser in the manner contemplated by this Agreement and the Time of Sale Memorandum to register such offer, sale or
delivery of the Securities under the Securities Act or, until such time as the Exchange Securities are issued pursuant to an effective registration statement, to qualify the Indenture under the Trust Indenture Act. 

  
 10 









 (w) The Securities are eligible for resale pursuant to Rule 144A and will
not be, at the Closing Date, of the same class as securities listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in a U.S. automated interdealer quotation system. 

(x) Neither the Company nor any of its subsidiaries or affiliates, nor any director or officer, nor, to the Company’s
knowledge, any employee, agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving
of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure an improper advantage in
contravention of any applicable anti-corruption laws; and the Company and its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintain policies and procedures
designed to promote and achieve compliance with such laws. 
 (y) The operations of the Company and its
subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening
America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency and applicable to the Company or its subsidiaries (collectively, the “Anti-Money Laundering
Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to
the knowledge of the Company, threatened. 
 (z) (i) Neither the Company nor any of its subsidiaries, nor any
director or officer thereof, nor, to the Company’s knowledge, any employee, agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (“Person”) that is, or is owned or controlled
by a Person that is: 
 (A) the subject of any sanctions administered or enforced by the U.S. Department of
Treasury’s Office of Foreign 

  
 11 









 
Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor

 (B) located, organized or resident in a country or territory that is the subject of Sanctions (including,
without limitation, Burma/Myanmar, Cuba, Iran, Libya, North Korea, Sudan and Syria). 
 (ii) The Company will
not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: 

(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the
time of such funding or facilitation, is the subject of Sanctions; or 
 (B) in any other manner that will
result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). 
 (iii) For the past 5 years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any
Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. 
 (aa) KPMG LLP, which expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) and any supporting schedules included in the
Time of Sale Memorandum, are independent public or certified public accountants within the meaning of the Rules of Professional Conduct/Code of Ethics (or similar rules) and Regulation S-X under the Securities Act and the Exchange Act, and any
non-audit services provided to the Company by KPMG LLP have been approved by the audit committee of the board of directors of the Company. 
 (bb) The financial statements, together with the related schedules (if any) and notes, included or incorporated by reference in the Time of Sale Memorandum present fairly in all material respects the
consolidated financial position of the entities to which they relate as of and at the dates indicated and the results of their operations and cash flows for the periods specified. Such financial statements have been prepared in accordance with
generally accepted accounting principles in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The financial data set forth or incorporated by reference in
the Time of Sale Memorandum under the caption “Summary—Summary Consolidated Financial 

  
 12 









 
Data” fairly presents in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Time of Sale Memorandum.
Nothing has come to the attention of the Company or the Guarantors that has caused the Company or any Guarantor to believe that the statistical and market-related data included or incorporated by reference in each of the Time of Sale Memorandum and
the Final Memorandum is not based on or derived from sources that are reliable and accurate in all material respects. 
 (cc) The Company and its subsidiaries own or possess adequate rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the conduct of their respective businesses, except in any such
instances that, individually or in the aggregate, are not reasonably expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; and the conduct of their respective businesses will not conflict in any material
respect with any such rights of others, and, except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum, the Company and its subsidiaries have not received any notice of any claim of infringement of or conflict with any
such rights of others, except in any such instances that, individually or in the aggregate, are not reasonably expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. 

(dd) The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and
have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective
businesses as described in each of the Time of Sale Memorandum and the Final Memorandum, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on
the Company and its subsidiaries, taken as a whole; and except as otherwise disclosed in each of the Time of Sale Memorandum and the Final Memorandum, neither the Company nor any of its subsidiaries has received notice of any revocation or
modification of any such material license, certificate, permit or authorization or has any reason to believe that any such material license, certificate, permit or authorization will not be renewed in the ordinary course. 

(ee) The Company and its subsidiaries have good and marketable title to, or have valid rights to lease or otherwise use,
all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title, except for
(x) Permitted Liens, (y) those existing under the Credit Agreement (as defined herein), the Company’s 6.625% Senior Secured Notes due 2018 or the Company’s 6.875% Senior Secured Notes due 2020 or (z) those that (i) do
not materially interfere with the use made and 

  
 13 









 
proposed to be made of such property by the Company and its subsidiaries or (ii) could not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the
Company and its subsidiaries, taken as a whole. 
 (ff) The Company and its subsidiaries have filed all federal,
state, local and foreign tax returns required to be filed through the date hereof and have paid all taxes shown as due on such returns, except in such instances that are reasonably expected to not have a material adverse effect on the Company and
its subsidiaries, taken as a whole; the Company and its subsidiaries have either paid or appropriately reserved under generally accepted accounting principles (“GAAP”) for all federal, state, local and foreign taxes required to be
paid through the date hereof, except in such instances that are reasonably expected to not have a material adverse effect on the Company and its subsidiaries, taken as a whole; and except as otherwise disclosed in each of the Time of Sale
Information and the Offering Memorandum, there is no material tax deficiency that has been, or that is expected to be, asserted against the Company or any of its Significant Subsidiaries or any Guarantor or any of their respective properties or
assets. 
 (gg) The Company, the Guarantors and the Significant Subsidiaries have insurance covering their
respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against material losses and risks and are reasonably believed to be adequate to protect the Company,
the Guarantors and the Significant Subsidiaries and their respective businesses; and neither the Company, nor the Guarantors nor any of the Significant Subsidiaries has (i) received notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to
obtain similar coverage from similar insurers as may be necessary to continue its business. 
 (hh) None of the
Company or any of the Guarantors has taken or will take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Securities. 
 (ii) On and immediately after the Closing Date, the Company
and each Guarantor (after giving effect to the issuance of the Securities and the other transactions related thereto as described in each of the Time of Sale Memorandum and the Final Memorandum) will be Solvent. As used in this paragraph, the term
“Solvent” means, with respect to a particular date and entity, that on such date (i) the fair value of the assets of such entity and its consolidated subsidiaries taken as a whole is not less than the total amount of
liabilities of such entity and its consolidated subsidiaries taken as a whole; (ii) such entity is able to pay its debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of
business; (iii) assuming consummation of the issuance of the Securities as contemplated by this Agreement, the Time of Sale 

  
 14 









 
Memorandum and the Final Memorandum, such entity is not incurring debts or liabilities beyond its ability to pay as such debts and liabilities mature; and (iv) such entity is not engaged in
any business or transaction, and does not propose to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which such
entity is engaged. 
 (jj) The Securities, upon issuance, will constitute “senior indebtedness” as such
term is defined in any indenture or agreement governing any outstanding subordinated indebtedness of the Company. 
 (kk) Except pursuant to the Credit Agreement and the Indentures dated as of January 20, 2010 among the Company, the guarantors party thereto and Wells Fargo Bank, N.A. as trustee regarding the
Company’s 6.625% Senior Secured Notes due 2018 and 6.875% Senior Secured Notes due 2020, no subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject,
from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such
subsidiary’s properties or assets to the Company or any other subsidiary of the Company. 
 (ll) Neither the
Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Initial Purchaser for a brokerage commission,
finder’s fee or like payment in connection with the offering and sale of the Securities. 
 (mm) The Company
and its subsidiaries and their respective officers and directors are in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act,” which term, as used herein,
includes the rules and regulations of the Commission promulgated thereunder). 
 (nn) The Company and its
subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is
accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and
procedures as required by Rule 13a-15 of the Exchange Act. 

  
 15 









 (oo) The Company and its subsidiaries maintain systems of “internal
control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and
principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The
Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive data in
eXtensible Business Reporting Language included or incorporated by reference in each of the Time of Sale Memorandum and the Final Memorandum is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as
disclosed in each of the Time of Sale Memorandum and the Final Memorandum, there are no material weaknesses or significant deficiencies in the Company’s internal controls. The Company’s auditors and the audit committee of the board of
directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the Company’s
ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial
reporting. 
 (pp) Neither the Company nor any of its subsidiaries nor any agent thereof acting on their behalf
has taken, and none of them will take, any action that might cause this Agreement or the issuance or sale of the Securities to violate Regulation T, Regulation U or Regulation X of the Board of Governors of the Federal Reserve System. 

(qq) No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of
the Exchange Act) contained in any of the Time of Sale Memorandum or the Final Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 

(rr) Except as otherwise disclosed in the Time of Sale Memorandum and the Final Memorandum or as would not reasonably be
expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, (i) each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), for which the 

  
 16 









 
Company or any member of its “Controlled Group” (defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the
Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and
regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions
effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in
Section 412 of the Code, whether or not waived, has occurred or is reasonably expected to occur; (iv) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on
those assumptions used to fund such Plan); (v) no “reportable event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur; and (vi) neither the Company nor any member of the
Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including a
“multiemployer plan,” within the meaning of Section 4001(a)(3) of ERISA). 
 (ss) No labor
disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company or any of the Guarantors, is threatened, except as would not reasonably be expected to have a material adverse effect on
the Company and its subsidiaries, taken as a whole. 
 (tt) No relationship, direct or indirect, exists between
or among any of Company or any affiliate of the Company, on the one hand, and any director, officer, member, stockholder, customer or supplier of the Company or any affiliate of the Company, on the other hand, which is required by the Securities Act
to be disclosed in a registration statement on Form S-1 which is not so disclosed in the Time of Sale Memorandum. There are no outstanding loans, advances (except advances for business expenses in the ordinary course of business) or guarantees of
indebtedness by the Company or any affiliate of the Company to or for the benefit of any of the officers or directors of the Company or any affiliate of the Company or any of their respective family members. 

(uu) The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

 2. Agreements to Sell and Purchase. Each of the Company and the Guarantors hereby agrees to issue and sell to the
Initial Purchasers, and each Initial Purchaser, upon 

  
 17 









 
the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company and the
Guarantors the respective principal amount of Securities set forth in Schedule I hereto opposite its name at a purchase price of 98.75% of the principal amount thereof (the “Purchase Price”), plus accrued and unpaid interest,
if any, from January 22, 2013 to the Closing Date (as defined below). 
 3. Terms of Offering. You have advised the
Company that the Initial Purchasers will make an offering of the Securities purchased by the Initial Purchasers hereunder as soon as practicable after this Agreement is entered into as in your judgment is advisable. 

4. Payment and Delivery. Payment for the Securities shall be made to the Company, deposited in trust as directed by the Company or
otherwise deposited in an account specified by the Company in Federal or other funds immediately available in New York City against delivery of such Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York
City time, on January 22, 2013, or at such other time on the same or such other date, not later than January 29, 2013, as shall be designated in writing by Morgan Stanley & Co. LLC. The time and date of such payment are
hereinafter referred to as the “Closing Date.” Such delivery and payment shall be made at the offices of Davis Polk & Wardwell LLP, 1600 El Camino Real, Menlo Park, California 94025 (or such other place as may be agreed to
by the Company and Morgan Stanley & Co. LLC). The Company hereby acknowledges that circumstances under which Morgan Stanley & Co. LLC may provide notice to postpone the Closing Date as originally scheduled include, but are in no
way limited to, any determination by the Company or the Initial Purchasers to recirculate to investors copies of an amended or supplemented Preliminary Memorandum or a delay as contemplated by the provisions of Section 10 hereof. 

The Securities shall be in definitive form or global form, as specified by the Representatives, and registered in such names and in such
denominations as the Representatives shall request in writing not later than one full business day prior to the Closing Date. The Securities shall be delivered to the Representatives on the Closing Date for the respective accounts of the Initial
Purchasers, with any transfer taxes payable in connection with the transfer of the Securities to the Initial Purchasers duly paid, against payment of the Purchase Price therefor plus accrued interest, if any, to the date of payment and delivery.
Time shall be of the essence, and delivery at the time and place specified in this Agreement is a condition to the obligations of the Initial Purchasers. 

  
 18 









 5. Conditions to the Initial Purchasers’ Obligations. The several obligations of
the Initial Purchasers to purchase and pay for the Securities as provided herein on the Closing Date are subject to the satisfaction or waiver, as determined by the Representatives in their sole discretion of the following conditions precedent on or
prior to the Closing Date: 
 (a) Subsequent to the execution and delivery of this Agreement and prior to the
Closing Date: 
 (i) there shall not have occurred any downgrading, nor shall any notice have been given of any
intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded the Company of any of the securities of the Company or any of its subsidiaries or in the
rating outlook for the Company by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act; and 

(ii) there shall not have occurred any change, or any development involving a prospective change, in the condition,
financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Memorandum (exclusive of any amendment or supplement thereto) provided to the
prospective purchasers of the Securities that, in your judgment, is material and adverse and that makes it, in your judgment, impracticable to market the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum
(exclusive of any amendment or supplement thereto). 
 (b) The representations and warranties of the Company and
the Guarantors contained in this Agreement shall be true and correct on and as of the Time of Sale and on and as of the Closing Date as if made on and as of the Closing Date; the statements of the Company’s officers made pursuant to any
certificate delivered in accordance with the provisions hereof shall be true and correct on and as of the date made and on and as of the Closing Date; the Company and the Guarantors shall have performed all covenants and agreements and satisfied all
conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date. 
 (c) The
Initial Purchasers shall have received on the Closing Date a certificate, dated the Closing Date and signed by the Chief Executive Officer or President of the Company and each Guarantor and the Chief Financial Officer or Chief Accounting Officer of
the Company and each Guarantor to the effect set forth in Section 5(a)(i) and 5(a)(ii), and further to the effect that the representations and warranties of the Company and the Guarantors contained in this Agreement were true and correct as of
the Time of Sale and are true and correct as of the Closing Date; that the Company and the Guarantors have complied with all of the agreements and satisfied all of the conditions on their part to be performed or satisfied hereunder on or before the
Closing Date; and that the sale of the Securities has not been enjoined (temporarily or permanently). 
 (d) The
Initial Purchasers shall have received on the Closing Date an opinion and negative assurance letter of Cooley LLP, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives.


  
 19 









 (e) The Initial Purchasers shall have received on the Closing Date an
opinion and negative assurance letter of Davis Polk & Wardwell LLP, counsel for the Initial Purchasers, dated the Closing Date, with respect to such matters as may be reasonably requested by the Initial Purchasers. 

(f) On the date hereof, the Initial Purchasers shall have received from KPMG LLP, the independent registered public
accounting firm for the Company, one or more “comfort letters” dated the date hereof addressed to the Initial Purchasers, in form and substance satisfactory to the Representatives, covering the financial information in the Time of Sale
Memorandum, the Final Memorandum and other customary matters. In addition, on the Closing Date, the Initial Purchasers shall have received from such accountants a “bring-down comfort letter” dated the Closing Date addressed to the Initial
Purchasers, in form and substance satisfactory to the Representatives, in the form of the “comfort letter” delivered on the date hereof, except that (i) it shall cover any amendment or supplement to the Final Memorandum and
(ii) procedures shall be brought down to a date no more than 3 days prior to the Closing Date. 
 (g) The
Company and the Guarantors shall have executed and delivered the Indenture, in form and substance reasonably satisfactory to the Initial Purchasers, and the Initial Purchasers shall have received executed copies thereof. The Company and the
Guarantors shall have executed and delivered the Registration Rights Agreement, in form and substance reasonably satisfactory to the Initial Purchasers, and the Initial Purchasers shall have received such executed counterparts. 

(h) The sale of the Securities shall not be enjoined (temporarily or permanently) on the Closing Date. 

(i) On or before the Closing Date, the Initial Purchasers and counsel for the Initial Purchasers shall have received such
information, documents, letters and opinions as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the
representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained. 
 If any
condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representatives by notice to the Company at any time on or prior to the Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Sections 6(g), 8 and 11 hereof shall at all times be effective and shall survive such termination. 

6. Covenants of the Company. Each of the Company and the Guarantors, jointly and severally, covenants with each Initial Purchaser
as follows: 
 (a) To furnish to you in New York City, without charge, as promptly as practicable following the
Time of Sale and in any event not later than the 

  
 20 









 
second business day following the date hereof and during the period mentioned in Section 6(d) or (e), as many copies of the Time of Sale Memorandum, the Final Memorandum, any documents
incorporated by reference therein and any supplements and amendments thereto as you may reasonably request. 

(b) Before amending or supplementing the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum, to
furnish to you a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which you reasonably object, provided that nothing in this section shall prohibit the Company from complying with its
obligations under law or the rules of the NASDAQ Global Select Market. 
 (c) To furnish to you a copy of each
proposed Additional Written Offering Communication to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed Additional Written Offering Communication to which you reasonably object.

 (d) If the Time of Sale Memorandum is being used to solicit offers to buy the Securities at a time when the
Final Memorandum is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Memorandum in order to make the statements therein, in the
light of the circumstances under which they are made, not misleading or if, in the judgment of the Representatives or counsel for the Initial Purchasers or the Company, it is necessary to amend or supplement the Time of Sale Memorandum to comply
with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchasers and to any dealer upon request, either amendments or supplements to the Time of Sale Memorandum so that the statements in the Time of Sale
Memorandum as so amended or supplemented will not, in the light of the circumstances under which they are made, when delivered to a Subsequent Purchaser, be misleading or so that the Time of Sale Memorandum, as amended or supplemented, will comply
with applicable law. 
 (e) If, during such period after the date hereof and prior to the date on which all of
the Securities shall have been sold by the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum in order to make the statements therein, in the light of the
circumstances under which they are made, not misleading or if, in the judgment of the Representatives or counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to comply with applicable law, forthwith to
prepare and furnish, at its own expense, to the Initial Purchasers, either amendments or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in the light of the circumstances
under which they are made, when delivered to a Subsequent Purchaser, be misleading or so that the Final Memorandum, as amended or supplemented, will comply with applicable law. 

  
 21 









 (f) (i) To cooperate with the Representatives and counsel for the Initial
Purchasers to qualify or register (or to obtain exemptions from qualifying or registering) all or any part of the Securities for offer and sale under the securities laws of the several states of the United States, the provinces of Canada or any
other jurisdictions designated by the Initial Purchasers, and to comply with such laws and to continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Securities; (ii) to advise the
Representatives promptly in writing of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any
such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, to use its commercially reasonable efforts to obtain the withdrawal thereof at the earliest possible moment; (iii) to advise
the Representatives in writing of the issuance by any governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Memorandum, any Additional Written Offering Communication or the Final Memorandum or
the initiation or threatening of any proceeding for that purpose, and in the event of the issuance of any such order, to use its commercially reasonable efforts to obtain the withdrawal thereof at the earliest possible moment; and (iv) to
advise the Representatives promptly in writing of the occurrence of any event at any time prior to the completion of the initial offering of the Securities as a result of which any of the Time of Sale Memorandum, any Additional Written Offering
Communication or the Final Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing when such Time of Sale Memorandum, Additional Written Offering Communication or the Final Memorandum is delivered to a purchaser, not misleading. Notwithstanding the foregoing, none of the Company or any of the Guarantors shall be required
to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. 

(g) Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay
or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel and the Company’s accountants and other advisors in
connection with the issuance and sale of the Securities and all other fees or expenses in connection with the issuance and sale of the Securities, including, without limitation, in connection with the preparation, printing, filing, shipping and
distribution of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, any Additional Written Offering Communication and any amendments and supplements to any of the foregoing, this Agreement, the Indenture, the Registration
Rights Agreement, the Securities and Exchange Securities, including all printing costs associated therewith, and the delivering of copies thereof to the Initial Purchasers, (ii) all costs and expenses related to the


  
 22 









 
transfer and delivery of the Securities and the Exchange Securities to the Initial Purchasers, including any transfer or other taxes payable thereon, (iii) the cost of printing or producing
any Blue Sky or legal investment memorandum in connection with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification of the Securities for offer and sale under state securities laws as
provided in Section 6(f) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection with such qualification and in connection with the Blue Sky or legal investment memorandum,
(iv) any fees charged by rating agencies for the rating of the Securities or the Exchange Securities, (v) the fees and expenses, if any, incurred in connection with the admission of the Securities for trading any appropriate market system,
(vi) the costs and charges of the Trustee and any transfer agent, registrar or depositary, (vii) the cost of the preparation, issuance and delivery of the Securities, (viii) the costs and expenses of the Company relating to investor
presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses
associated with production of road show slides and graphics, and fees and expenses of any consultants engaged by the Company in connection with the road show presentations, if any, (ix) the document production charges and expenses associated
with printing this Agreement and (x) all other cost and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that except as
provided in this Section, Section 8, and the last paragraph of Section 11, the Initial Purchasers will pay all of their costs and expenses, including fees and disbursements of their counsel. 

(h) Neither the Company nor any Affiliate will sell, offer for sale or solicit offers to buy or otherwise negotiate in
respect of any security (as defined in the Securities Act) which if, as a result of the doctrine of “integration” referred to in Rule 502 under the Securities Act, such offer or sale would render invalid (for the purpose of (i) the
sale of the Securities by the Company to the Initial Purchasers, (ii) the resale of the Securities by the Initial Purchasers to the Subsequent Purchasers or (iii) the resale of the Securities by such Subsequent Purchasers to others) the
exemption from the registration requirements of the Securities Act provided by Section 4(2) thereof or by Rule 144A or by Regulation S thereunder or otherwise. 

(i) Not to solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation or
general advertising (as those terms are used in Rule 502(c) of Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. 

(j) (i) Prior to the Closing Date, to furnish to the Initial Purchasers, as soon as they have been prepared, a copy of any
audited annual financial statements or unaudited interim financial statements of the Company for any 

  
 23 









 
period subsequent to the period covered by the most recent financial statements appearing in the Time of Sale Memorandum and the Final Memorandum; and (ii) while any of the Securities remain
outstanding and are “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act, to make available, upon request, to any holder of such Securities and any prospective purchasers thereof the information specified
in Rule 144A(d)(4) under the Securities Act, unless as such time the Company shall be subject to Section 13 or 15(d) of the Exchange Act and shall have filed all reports required to be filed pursuant to such Sections and the related rules and
regulations of the Commission. 
 (k) None of the Company, its Affiliates or any person acting on its or their
behalf (other than the Initial Purchasers) will engage in any directed selling efforts (as that term is defined in Regulation S) with respect to the Securities, and the Company and its Affiliates and each person acting on its or their behalf (other
than the Initial Purchasers) will comply with the offering restrictions requirement of Regulation S. 
 (l) The
Company will not, and will not permit any of its affiliates (as defined in Rule 144 under the Securities Act) to resell any of the Securities that have been acquired by any of them, except for Securities purchased by the Company or any of its
affiliates and resold in a transaction registered under the Securities Act. 
 (m) Not to take any action
prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities contemplated hereby. 
 (n) To apply the net proceeds from the sale of the Securities in the manner described under the caption “Use of Proceeds” in the Time of Sale Memorandum and the Final Memorandum. 

(o) During the period of 60 days following the date hereof, the Company will not and will not permit any of its
subsidiaries to, without the prior written consent of Morgan Stanley & Co. LLC (which consent may be withheld at the sole discretion of Morgan Stanley & Co. LLC), directly or indirectly, sell, offer, contract or grant any option to
sell, pledge, transfer or establish an open “put equivalent position” within the meaning of Rule 16a-1 under the Exchange Act, or otherwise dispose of or transfer, or announce the offering of, or file any registration statement under the
Securities Act in respect of, any debt securities of the Company or any subsidiary of the Company having a tenor of more than one year or securities exchangeable for or convertible into debt securities of the Company or any subsidiary of the Company
having a tenor of more than one year (other than as contemplated by this Agreement and to register the Exchange Securities). 

7. Offering of Securities; Restrictions on Transfer. (a) Each Initial Purchaser, severally and not jointly, represents and
warrants that such Initial Purchaser is a qualified 

  
 24 









 
institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not jointly, agrees with the Company that (i) it will
not solicit offers for, or offer or sell, such Securities by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning
of Section 4(2) of the Securities Act and (ii) it will solicit offers for such Securities only from, and will offer such Securities only to, persons that it reasonably believes to be (A) in the case of offers inside the United States,
QIBs or (B) in the case of offers outside the United States, to persons other than U.S. persons (“foreign purchasers,” which term shall include dealers or other professional fiduciaries in the United States acting on a
discretionary basis for foreign beneficial owners (other than an estate or trust)) in reliance upon Regulation S under the Securities Act. 
 (b) Each Initial Purchaser, severally and not jointly, represents, warrants, and agrees with respect to offers and sales outside the United States that: 

(i) such Initial Purchaser has offered the Securities and will offer and sell the Securities (A) as part of its
distribution at any time and (B) otherwise until 40 days after the later of the commencement of the offering and the Closing Date, only in accordance with Rule 903 of Regulation S or as otherwise permitted in Section 7(a); accordingly,
neither such Initial Purchaser, its Affiliates nor any persons acting on its or their behalf have engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the Securities, and any such Initial
Purchaser, its Affiliates and any such persons have complied and will comply with the offering restrictions requirement of Regulation S; 
 (ii) such Initial Purchaser, in relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”), has
represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State it has not made and will not make an offer of Securities to the public in that Relevant Member State,
other than: 
 (A) to any legal entity which is a qualified investor as defined in the Prospectus Directive;

 (B) to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD
Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of Morgan Stanley & Co. LLC on
behalf of the Initial Purchasers for any such offer; or 

  
 25 









 (C) in any other circumstances falling within Article 3 of the Prospectus
Directive, provided that no such offer of Securities shall require the Company or any Initial Purchaser to publish a prospectus pursuant to Article 3 of the Prospectus Directive. 
 For the purposes of the above, the expression an “offer of Securities to the public” in relation to any Securities in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the Securities to be offered so as to enable an investor to decide to purchase or subscribe for the Securities, as the same may be varied in that Member State by any measure implementing
the Prospectus Directive in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and
includes any relevant implementing measure in that Member State, and the expression “2010 PD Amending Directive” means Directive 3010/73/EU. 
 (iii) such Initial Purchaser has represented and agreed that it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to
engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) received by it in connection with the issue or sale of the Securities in circumstances in which Section 21(1) of such Act does
not apply to us and it has complied and will comply with all applicable provisions of such Act with respect to anything done by it in relation to any Securities in, from or otherwise involving the United Kingdom; and 

(iv) such Initial Purchaser agrees that, at or prior to confirmation of sales of the Securities, it will have sent to each
distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases Securities from it during the restricted period a confirmation or notice to substantially the following effect: 

“The Securities covered hereby have not been registered under the U.S. Securities Act of 1933 (the “Securities
Act”) and may not be offered and sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or (ii) otherwise until 40 days after the later of the commencement of
the offering and the Closing Date, except in either case in accordance with Regulation S (or Rule 144A if available) under the Securities Act. Terms used above have the meaning given to them by Regulation S.” 

Terms used in this Section 7(b) have the meanings given to them by Regulation S. 

  
 26 









 (c) Each Initial Purchaser acknowledges that: 

(i) such Initial Purchaser understands that no action has been or will be taken in any jurisdiction by the Company that
would permit a public offering of the Securities, or possession or distribution of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or any other offering or publicity material relating to the Securities, in any country
or jurisdiction where action for that purpose is required; and 
 (ii) neither the offer nor sale of the
Securities has been registered under the Securities Act and the Securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in accordance with Rule 144A or Regulation S under the
Securities Act or pursuant to another exemption from the registration requirements of the Securities Act. 
 8. Indemnity and
Contribution. (a) Each of the Company and the Guarantors, jointly and severally, agrees to indemnify and hold harmless each Initial Purchaser, its directors and officers and each person, if any, who controls any Initial Purchaser within the
meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of each Initial Purchaser within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims,
damages, liabilities and expenses (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim, as such expenses are incurred) caused by any untrue statement
or alleged untrue statement of a material fact contained in the Preliminary Memorandum, the Time of Sale Memorandum or any amendment or supplement thereto, any Additional Written Offering Communication prepared by or on behalf of, used by, referred
to or approved by the Company, or the Final Memorandum or any amendment or supplement thereto, or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein in the light of the circumstances
under which they were made not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Initial
Purchaser furnished to the Company by such Initial Purchaser through Morgan Stanley & Co. LLC expressly for use in the Preliminary Memorandum, the Pricing Supplement, any Additional Written Offering Communication or the Final Memorandum (or
any amendment or supplement thereto). The indemnity agreement set forth in this Section 8(a) shall be in addition to any liabilities that the Company and the Guarantors may otherwise have. 

(b) Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company, each Guarantor,
each of their respective directors and officers and each person, if any, who controls the Company or any Guarantor within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the
foregoing indemnity from the Company to such Initial Purchaser, but only with reference to information relating to such Initial Purchaser furnished to the Company by such Initial Purchaser through Morgan Stanley & Co. LLC expressly


  
 27 









 
for use in the Preliminary Memorandum, the Pricing Supplement, any Additional Written Offering Communication or the Final Memorandum (or any amendment or supplement thereto). Each of the Company
and the Guarantors hereby acknowledges that the only information that the Initial Purchasers through Morgan Stanley & Co. LLC have furnished to the Company expressly for use in the Preliminary Memorandum, the Time of Sale Memorandum, any
Additional Written Communication or the Final Memorandum (or any amendment or supplement thereto) are the statements set forth in the 4th, 9th and 10th paragraphs, and the 4th and 5th sentences of the 8th paragraph, under the caption “Plan of Distribution” in the Preliminary Memorandum and the Final Memorandum.
The indemnity agreement set forth in this Section 8(b) shall be in addition to any liabilities that each Initial Purchaser may otherwise have. 
 (c) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such
person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the “indemnifying party”) in writing; provided, however, that the failure to so notify the indemnifying
party will not relieve it from any liability which it may have to any indemnified party under Section 8(a) or 8(b) except to the extent that it has been materially prejudiced by such failure (through the forfeiture of substantive rights and
defenses) and shall not relieve the indemnifying party from any liability that the indemnifying party may have to an indemnified party other than under Section 8(a) or 8(b). The indemnifying party, upon request of the indemnified party, shall
retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonable fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the
indemnified party shall have mutually agreed to the retention of such counsel, (ii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party, (iii) the indemnified party
shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnified party, or (iv) the named parties to any such proceeding (including any impleaded
parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying
party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate firm (in addition
to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Morgan Stanley & Co. LLC, in the case of parties indemnified
pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The 

  
 28 









 
indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it
shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying
party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending
or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such proceeding and does not include any statements as to or any findings of fault, culpability or failure to act by or on behalf of any indemnified party. 

(d) To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Guarantors on the one hand and the
Initial Purchasers on the other hand from the offering of the Securities or (ii) if the allocation provided by clause 8(d) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause 8(d) above but also the relative fault of the Company and the Guarantors on the one hand and of the Initial Purchasers on the other hand in connection with the statements or omissions that resulted in such losses, claims,
damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Guarantors on the one hand and the Initial Purchasers on the other hand in connection with the offering of the
Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (before deducting expenses) received by the Company and the total discounts and commissions received by the Initial
Purchasers bear to the aggregate offering price of the Securities. The relative fault of the Company and the Guarantors on the one hand and of the Initial Purchasers on the other hand shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the 

  
 29 









 
Company or the Guarantors, or by the Initial Purchasers, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of Securities they have purchased hereunder as set forth opposite their names in
Schedule I hereto, and not joint. 
 (e) The Company and the Guarantors and the Initial Purchasers agree
that it would not be just or equitable if contribution pursuant to Section 8(d) were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that
does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection
(e), no Initial Purchaser shall be obligated to make contributions hereunder that in the aggregate exceed the total discounts, commissions and other compensation received by such Initial Purchaser under this Agreement, less the aggregate amount of
any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or
remedies which may otherwise be available to any indemnified party at law or in equity. 
 (f) The indemnity and
contribution provisions contained in this Section 8 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination
of this Agreement, (ii) any investigation made by or on behalf of any Initial Purchaser, any person controlling any Initial Purchaser or any affiliate of any Initial Purchaser or by or on behalf of the Company, its officers or directors or any
person controlling the Company and (iii) acceptance of and payment for any of the Securities. 
 9. Termination. The
Representatives may terminate this Agreement by notice given by you to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on, or
by, as the case may be, any of the New York Stock Exchange, the NASDAQ Stock Market or the over the counter market, (ii) trading of any securities issued or guaranteed by the Company or any of the Guarantors shall have been suspended on any
exchange or in any over the counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States or other relevant jurisdiction shall have occurred, (iv) any moratorium on commercial
banking activities 

  
 30 









 
shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any
calamity or crisis that, in the Representatives’ judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the judgment of the Representatives, impracticable or inadvisable
to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum or the Final Memorandum. 
 10. Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. 

If, on the Closing Date, any one or more of the Initial Purchasers shall fail or refuse to purchase Securities that it or they have
agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase is not more than one tenth of the aggregate principal
amount of Securities to be purchased on such date, the other Initial Purchasers shall be obligated severally in the proportions that the principal amount of Securities set forth opposite their respective names in Schedule I bears to the
aggregate principal amount of Securities set forth opposite the names of all such non defaulting Initial Purchasers, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Initial Purchasers,
to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on the Closing Date; provided that in no event shall the principal amount of Securities that any Initial
Purchaser has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of one ninth of such principal amount of Securities without the written consent of such Initial Purchaser. If, on the
Closing Date any Initial Purchaser or Initial Purchasers shall fail or refuse to purchase Securities which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of Securities with respect to which such default
occurs is more than one tenth of the aggregate principal amount of Securities to be purchased on the Closing Date, and arrangements satisfactory to the non-defaulting Initial Purchasers and the Company for the purchase of such Securities are not
made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non defaulting Initial Purchaser or of the Company or any Guarantor except that the provisions of Sections 6(g), 8 and 11 hereof shall
at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required
changes, if any, in the Time of Sale Memorandum, the Final Memorandum or in any other documents or arrangements may be effected. As used in this Agreement, the term “Initial Purchaser” shall be deemed to include any person substituted for
a defaulting Initial Purchaser under this Section 10. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 

11. Reimbursement of the Expenses of the Initial Purchasers. If this Agreement shall be terminated by the Representatives pursuant
to Section 9 or because of any failure or refusal on the part of the Company or any Guarantor to comply with the terms or to 

  
 31 









 
fulfill any of the conditions of this Agreement, or if for any reason the Company or any Guarantor shall be unable to perform their obligations under this Agreement, the Company and the
Guarantors, jointly and severally, will reimburse the Initial Purchasers, severally, upon demand for all out of pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Initial Purchasers in connection with
this Agreement or the offering contemplated hereunder. 
 12. Entire Agreement. (a) This Agreement, together with
any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Company and the Initial Purchasers
with respect to the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, the conduct of the offering, and the purchase and sale of the Securities. 

(b) This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company, the
Guarantors and the Initial Purchasers, or any of them, with respect to the subject matter hereof. 
 (c) The
Company acknowledges that in connection with the offering of the Securities: (i) the Initial Purchasers have acted at arms length, are not agents of, and owe no fiduciary duties to, the Company, the Guarantors or any other person, (ii) the
Initial Purchasers owe the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement) if any, (iii) the Initial Purchasers may have interests that differ
from those of the Company and the Guarantors, and (iv) the Initial Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby, and the Company and the Guarantors have consulted
their own legal, accounting, regulatory and tax advisors to the extent they deemed appropriate. The Company and the Guarantors waive to the full extent permitted by applicable law any claims they may have against the Initial Purchasers arising from
an alleged breach of fiduciary duty in connection with the offering of the Securities. 
 13. Counterparts. This
Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed counterpart of a signature page to this
Agreement by telecopier, facsimile or other electronic transmission (i.e., a “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart thereof. 

14. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the
indemnified parties referred to in Section 8 hereof, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any Subsequent Purchaser or
other purchaser of the Securities as such from any of the Initial Purchasers merely by reason of such purchase. 

  
 32 









 15. Partial Unenforceability. The invalidity or unenforceability of any section,
paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or
unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. 
 16. Authority of the Representative. Any action by the Initial Purchasers hereunder may be taken by the Representatives on behalf of the Initial Purchasers, and any such action taken by the
Representatives shall be binding upon the Initial Purchasers. 
 17. Survival. The respective indemnities, rights of
contribution, representations, warranties and agreements of the Company, the Guarantors and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company, the Guarantors or the Initial Purchasers pursuant to this
Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf
of the Company, the Guarantors or the Initial Purchasers. 
 18. Applicable Law. This Agreement shall be governed by and
construed in accordance with the internal laws of the State of New York. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be
instituted in the federal courts of the United States of America located in the City and County of New York or the courts of the State of New York in each case located in the City and County of New York (collectively, the “Specified
Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for suits, actions, or proceedings instituted in regard to the enforcement of a judgment of any Specified Court in a Related Proceeding (a “Related
Judgment”), as to which such jurisdiction is non-exclusive) of the Specified Courts in any Related Proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective
service of process for any Related Proceeding brought in any Specified Court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any Specified Proceeding in the Specified Courts and irrevocably and
unconditionally waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought in any Specified Court has been brought in an inconvenient forum. 

19. Headings. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be
deemed a part of this Agreement. 
 20. Notices. All communications hereunder shall be in writing and effective only upon
receipt and if to the Initial Purchasers shall be delivered, mailed or sent to you in care of Morgan Stanley & Co. LLC, at 1585 Broadway, New York, New York 10036, Attention: High Yield Syndicate Desk, with a copy to the Legal Department,
and in care of J.P. Morgan Securities LLC, at 383 Madison Avenue, New York, Attention: Earl 

  
 33 









 
Dowling; and if to the Company shall be delivered, mailed or sent to 130 Holger Way, San Jose, California 95134, Attention: Chief Financial Officer, with a copy to General Counsel, and with a
copy to Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304, Attention: Nancy H. Wojtas. 
 [Signature Pages Follow]


  
 34 









 If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. 

 

			
	 Very truly yours,
  

BROCADE COMMUNICATIONS SYSTEMS, INC.

		
	By:	 	 /s/ Jean Furter

		 	Name: Jean Furter
		 	Title: Vice President and Treasurer


 [Signature page to Purchase Agreement] 







 
			
	 INRANGE TECHNOLOGIES CORPORATION

 

	By:	 	 /s/ Jean Furter

		 	Name: Jean Furter
		 	 Title:   Treasurer

 

	 MCDATA SERVICES CORPORATION

 

	By:	 	 /s/ Jean Furter

		 	Name: Jean Furter
		 	 Title:   Treasurer

 

	 FOUNDRY NETWORKS, LLC

 

	By:	 	 /s/ Jean Furter

		 	Name: Jean Furter
		 	 Title:   Treasurer

 

	 VYATTA, INC.

 

	By:	 	 /s/ Jean Furter

		 	Name: Jean Furter
		 	Title:   Vice President and Treasurer


 [Signature page to Purchase Agreement] 








			
	 Morgan Stanley & Co. LLC
 J.P. Morgan Securities LLC
  

Acting on behalf of themselves and as the Representatives of the several Initial Purchasers named in Schedule I hereto.

 
 By: Morgan Stanley & Co. LLC

 

	By:	 	 /s/ Andrew Earls

		 	Name: Andrew Earls
		 	 Title:   Managing Director

 

	 By: J.P. Morgan Securities LLC

 

	By:	 	 /s/ Earl Dowling

		 	Name: Earl Dowling
		 	Title:   Executive Director

 [Signature page to Purchase Agreement] 







 SCHEDULE I 

 

					
	 Initial Purchaser
	  	PRINCIPAL AMOUNT of
Securities to be Purchased	 
	 Morgan Stanley & Co. LLC
	  	$	135,000,000	  
	 J.P. Morgan Securities LLC
	  	 	105,000,000	  
	 Merrill Lynch, Pierce, Fenner & Smith

                   
  Incorporated
	  	 	30,000,000	  
	 HSBC Securities (USA) Inc.
	  	 	15,000,000	  
	 Scotia Capital (USA) Inc.
	  	 	15,000,000	  
		  	  
	  
	 
	 Total:
	  	$	300,000,000	  
		  	  
	  
	 


  
 I-1









 SCHEDULE II 

Time of Sale Memorandum 
  

	1.	Preliminary Memorandum issued January 16, 2013 

  

	2.	Pricing Supplement dated January 16, 2013 (attached) 


  
 II-1









 Pricing Supplement dated January 16, 2013 to 

Preliminary Offering Memorandum dated January 16, 2013 of 

BROCADE COMMUNICATIONS SYSTEMS, INC. 
 4.625% Senior Notes due 2023 
 This Pricing Supplement is qualified in its entirety by
reference to the preliminary offering memorandum dated January 16, 2013 (the “Preliminary Offering Memorandum”). The information in this Pricing Supplement supplements the Preliminary Offering Memorandum and supersedes the information
in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum. Terms used herein and not defined herein have the meanings assigned in the Preliminary Offering Memorandum. 

 

					
	Issuer:	 	Brocade Communications Systems, Inc. (the “Issuer”)
		
	Aggregate Principal Amount:	 	$300,000,000
		
	Title of Securities:	 	4.625% Senior Notes due 2023
		
	Final Maturity Date:	 	January 15, 2023
		
	Guarantors:	 	The notes will be guaranteed on a full, joint and several basis, by each of the Issuer’s domestic subsidiaries to the extent such subsidiaries guarantee the
indebtedness under its senior secured credit facility, its 6.875% Senior Secured Notes due 2020 or any of its other indebtedness. As of the issue date, the guarantors will comprise Inrange Technologies Corporation, McData Services Corporation,
Foundry Networks, LLC and Vyatta, Inc. The guarantees may be released under certain circumstances.
		
	Issue Price:	 	100.000%
		
	Gross Proceeds to the Issuer:	 	$300,000,000
		
	Coupon:	 	4.625%
		
	Yield:	 	4.625%
		
	Spread to Treasury:	 	280 basis points
		
	Benchmark:	 	1.625% UST due November 15, 2022









					
	Ratings:	 	B1/BB+ *
		
	Interest Payment Dates:	 	January 15 and July 15
		
	First Interest Payment Date:	 	July 15, 2013
		
	Optional Redemption:	 	At any time prior to January 15, 2018, the notes will be redeemable at the Issuer’s option, in whole or in part, at a redemption price equal to 100% of the
principal amount thereof, plus an “Applicable Premium” (as defined in the Preliminary Offering Memorandum) which is calculated by using a discount rate equal to the Treasury Rate plus 50 basis points, and accrued and unpaid interest, if
any, to but excluding the redemption date.
		
		 	At any time on or after January 15, 2018, the notes will be redeemable at the Issuer’s option, in whole or in part, at the redemption prices set forth below
(expressed as a percentage of principal amount), plus accrued and unpaid interest, if any, to but excluding the redemption date, if redeemed during the twelve-month period commencing on January 15 of the years indicated below:
		
		 	 Year
                                         
                       Price
 2018
                                         
   102.313%
 2019
                                         
   101.542%
 2020
                                         
   100.771%
 2021 and thereafter
                     100.000%

		
	Optional Redemption with Equity Proceeds:	 	At any time prior to January 15, 2016, up to 35% of the notes will be redeemable at the Issuer’s option with the net cash proceeds of one or more sales of
the Issuer’s capital stock at a redemption price equal to 104.625% of the principal amount thereof, plus accrued and unpaid interest, if any, to but excluding the redemption date.
		
	Change of Control:	 	101% plus accrued and unpaid interest, if any, to but excluding the repurchase date upon a Change of Control Triggering Event (as defined in the Preliminary Offering
Memorandum).
		
	CUSIP/ISIN Numbers:	 	 144A CUSIP: 111621 AL2
 144A ISIN: US111621AL25
 Regulation S CUSIP: U11097 AD1

Regulation S ISIN: USU11097AD17










					
	Joint-Lead and Bookrunning Managers:	 	 Morgan Stanley & Co. LLC
 J.P. Morgan Securities LLC

		
	Senior Co-Manager	 	 Merrill Lynch, Pierce, Fenner & Smith
                      Incorporated

		
	Co-Managers:	 	 HSBC Securities (USA) Inc.
 Scotia Capital (USA) Inc.

		
	Trade Date:	 	January 16, 2013
		
	Settlement Date:	 	January 22, 2013 (T+3)
		
	Distribution:	 	144A/Reg S with registration rights as set forth in the Preliminary Offering Memorandum

  

	*	Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. 


Other information (including financial information) presented in the Preliminary Offering Memorandum is deemed to have changed to the extent affected
by any changes described herein. 
 This material is confidential and is for your information only and is not intended to be used by
anyone other than you. This information does not purport to be a complete description of these securities or the offering. Please refer to the Preliminary Offering Memorandum for a complete description. 

This communication is being distributed solely to qualified institutional buyers, as defined in Rule 144A under the Securities Act of 1933, as
amended, and outside the United States solely to non-U.S. persons as defined under Regulation S. 
 This communication does not
constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. 







 SCHEDULE III 
 Significant Subsidiaries of the Company 
  

			
	 Name
	 	 Jurisdiction of Incorporation/Formation

	Foundry Networks, LLC	 	United States
		
	Brocade Switzerland Holdings GmbH	 	Switzerland
		
	Brocade Technology GmbH	 	Switzerland
		
	Brocade Communications Luxembourg SarL	 	Luxembourg
		
	Brocade Communications Luxembourg Holdings II SCS	 	Luxembourg
		
	Brocade Communications Luxembourg Holdings SarL	 	Luxembourg


  
 III-1